Amarin’s Vazkepa gets green light from SMC
Treatment will help reduce the risk of heart attacks and strokes for patients across Scotland
Read More
Tag: Vazkepa
Amarin’s Vazkepa secures NICE recommendation
It is the first treatment in its class to receive NICE approval for cardiovascular risk reduction
Read More
MHRA authorises Amarin’s heart drug Vazkepa
Drug demonstrated a 25% relative risk reduction in the first occurrence of major adverse cardiovascular events in REDUCE-IT trial
Read More
Kesimpta and Vazkepa among latest CHMP recommendations
Bumper meeting saw 13 new medicines recommended for approval
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
